NORD Awards Over $145,000 in Seed Grants to Advance Research for Four Critically Underserved Rare Diseases

QUINCY, Mass. — The National Organization for Rare Disorders (NORD®), the leading national nonprofit organization serving more than 30 million Americans living with rare diseases, has announced the recipients of its latest seed grant funding cycle. Totaling $145,000, this critical early-stage financial support is directed toward four highly innovative studies targeting critically underserved conditions that have historically lacked sufficient research attention, therapeutic options, and funding.

The newly awarded grants will support independent researchers conducting specialized scientific investigations into appendix cancer and pseudomyxoma peritonei (ACPMP), epidermodysplasia verruciformis (EV), Peutz-Jeghers syndrome (PJS), and partial trisomy 6q. Funding for this competitive grant cycle was made possible through the collaborative efforts and philanthropic contributions of the ACPMP Research Foundation—a dedicated NORD Member patient advocacy organization—alongside the pseudomyxoma peritonei, Peutz-Jeghers syndrome, and epidermodysplasia verruciformis patient communities, Dylan’s Rare Chromosome Dream Team, and the partial trisomy 6q community.

The funding arrives at a pivotal time for the rare disease community. With fewer than 5% of the approximately 10,000 known rare diseases currently having an FDA-approved therapy, early-stage seed grants serve as a vital catalyst for scientific discovery. These initial funds often provide researchers with the preliminary data and proof of concept required to secure larger investments from major entities such as the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), and private corporate sponsors.

Tracey Sikora, NORD Vice President of Research and Clinical Programs, expressed profound enthusiasm for the selected projects and the researchers behind them.

"Huge congratulations to our seed grant recipients — Drs. Sommariva, Ahuja, and Piovani! Their groundbreaking work represents a major leap forward for everyone affected by ACPMP, EV, PJS, and Partial Trisomy 6q," said Sikora. "We’re thrilled to champion innovative research that directly tackles the urgent, unmet needs of rare disease communities. We can’t wait to see how their insights will transform patient care and drive the future of rare disease research."

The recipients of NORD’s latest seed grant funding cycle encompass a diverse array of medical disciplines, utilizing cutting-edge methodologies ranging from advanced artificial intelligence to human stem cell modeling.

Dr. Sommariva’s study, titled “Analysis of TROP2 expression in Pseudomyxoma Peritonei (PMP),” addresses a significant clinical hurdle in the treatment of peritoneal malignancies. While cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) has been shown to greatly improve survival and quality of life for patients affected by pseudomyxoma peritonei, a substantial number of patients are ineligible for the procedure. Furthermore, available systemic chemotherapy options remain extremely limited, consisting essentially of palliative measures.

Sommariva’s research focuses on a promising therapeutic target known as trophoblast cell surface antigen 2 (TROP2). Specific agents targeting TROP2 have already been developed and approved by the FDA for other solid tumors, and preliminary results have confirmed overexpression in PMP tumor cells. The overarching aim of the study is to expand and strengthen this initial evidence while gaining deeper insights into the role of TROP2 in PMP pathogenesis. Establishing this foundational science is a critical prerequisite for identifying a new target for combinatory and adjuvant therapies, potentially opening doors to entirely new classes of treatment for patients who currently have few options.

NORD Awards Seed Grants to Advance Breakthroughs in Rare Disease Research - National Organization for Rare

In the field of rare dermatological and oncological genetics, Dr. Ahuja has been awarded funding for two distinct and impactful studies. The first, titled “Quantifying Malignancy and Treatment Effectiveness in EV: A Real-World Evidence Study of Surveillance Gaps,” investigates epidermodysplasia verruciformis (EV). Individuals with EV face an exceptionally high lifetime risk of skin cancer due to specific genetic mutations coupled with persistent human papillomavirus (HPV) infections. Despite this severe risk, real-world data concerning medical surveillance and long-term treatment outcomes has remained severely limited.

To overcome this data deficit, Ahuja’s project utilizes advanced, privacy-preserving artificial intelligence to securely extract critical clinical details—such as specific HPV subtypes, skin cancer recurrence patterns, and exact lesion locations—directly from unstructured dermatopathology reports. By translating this previously hidden information into robust real-world evidence, the research aims to quantify current surveillance gaps and help establish standardized, evidence-based care guidelines designed to improve malignancy-free survival for the EV community.

Ahuja’s second funded study, titled “Risk-Stratification of PJS Complications: A RWE Study on STK11 Variant Effects on Emergency Surgery and Cancer Onset,” shifts its focus to Peutz-Jeghers Syndrome (PJS). PJS is a rare hereditary condition that carries a high lifetime risk of severe gastrointestinal complications and aggressive cancers. Despite the severity of these risks, current clinical screening guidelines fail to account for the specific genetic mutations that actively drive the disease.

Utilizing the same innovative, privacy-preserving artificial intelligence framework, this project securely extracts complex genetic data from medical records to directly correlate specific STK11 mutations with the age of onset for emergency surgeries and malignancies. By transforming this real-world data into actionable evidence, the research team aims to help establish precision, variant-specific surveillance protocols. These protocols could prove vital in preventing life-threatening medical emergencies and significantly improving long-term health outcomes for individuals living with PJS.

The fourth seed grant was awarded to Dr. Piovani for a study titled “Partial Trisomy 6q: Clinical Characterization, Genomic Profiling, and Patient-Specific iPSC Models for Functional Disease Investigation.” This research aims to address the profound lack of scientific understanding surrounding partial trisomy 6q, a rare chromosomal disorder that currently makes accurate diagnosis and genetic counseling exceptionally challenging for affected individuals and their families.

Piovani’s project will combine detailed clinical and genomic information with patient-derived induced pluripotent stem cell (iPSC) models to investigate how partial trisomy 6q alters human development and to uncover the underlying biological mechanisms driving the disorder. The resulting data and cellular models will provide invaluable scientific resources for the broader rare disease community, laying a solid groundwork for future translational research aimed at improving patient care and clinical management.

Since its inception in 1989, NORD’s Rare Disease Research Grant Program has awarded more than $9 million in competitive research grants to advance scientific discovery for rare conditions that historically lack commercial incentive, treatment options, and dedicated funding. The grant program has successfully jump-started numerous urgent research initiatives, supported extensive peer-reviewed scientific publications, and directly contributed to the development and approval of two FDA-approved treatments.

The National Organization for Rare Disorders was founded in 1983 as a leading independent, nonprofit, and nonpartisan organization dedicated to improving the health, well-being, and long-term outlook for the more than 30 million Americans living with rare diseases. Working in active partnership with more than 350 disease-specific member patient organizations, as well as a comprehensive Rare Disease Centers of Excellence network spanning over 170 medical research institutions and children’s hospitals across the United States, NORD continues to advance clinical care, rigorous research, public education, and legislative advocacy on behalf of the entire rare disease community.

Nila Kartika Wati

Penulis aktif di HypePress yang membagikan konten inspiratif, informasi terkini, dan gaya hidup untuk generasi muda.

Artikel Bermanfaat dan Menghibur Lainnya